Cancer-related fatigue, inflammation and thyrotropin-releasing hormone

Current Aging Science

Volumn 5, Issue 3, 2012, Pages 195-202

  Kamath, Jayesh ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cancer; Fatigue; Immune system; Inflammation; Thyrotropin releasing hormone; TRH

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOKINE; ETANERCEPT; INTERLEUKIN 6; PLACEBO; PROTIRELIN; PROTIRELIN RECEPTOR; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR INHIBITOR;

AGING; ANTIINFLAMMATORY ACTIVITY; BEHAVIOR DISORDER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVOR; COMORBIDITY; CORTICOSTEROID THERAPY; HUMAN; INFLAMMATION; MORTALITY; NEOPLASM; PREVALENCE; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; AGING; ANTI-INFLAMMATORY AGENTS; COMORBIDITY; CONTROLLED CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATIGUE; HOMEOSTASIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEOPLASMS; QUALITY OF LIFE; SLEEP DISORDERS; THYROTROPIN-RELEASING HORMONE; TREATMENT OUTCOME;

EID: 84874914590     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609811205030005     Document Type: Review

References (58)

1. Troen BR. The biology of aging. Mt Sinai J Med 2003; 70: 3-22.
2. Franceschi C, Motta L, Motta M, et al. The extreme longevity: the state of the art in Italy. Exp Gerontol 2008; 43: 45-52.
3. Candore G, Colonna-Romano G, Balistreri CR, et al. Biology of longevity: role of the innate immune system. Rejuvenation Res 2006; 9: 1.
4. Candore G, Balistreri CR, Listì F, et al. Immunogenetics, gender, and longevity. Ann NY Acad Sci 2006; 1089: 516-37.
5. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp. Gerontol 2004; 39: 687-99.
6. World Health Organization Media Center. International Agency for Research on Cancer. Globocan 2008. IARC 2010. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
7. American Cancer Society. Cancer Facts and Figures 2007. American Cancer Society, Atlanta http://www.cancer.org/research/cancerfactsfigures/cancer-facts-figures-2007.
8. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-67.
9. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology 2002; 16: 217-26.
10. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumor immunity: effector response to tumor and role of the microenvironment. Lancet 2008; 371: 771-83.
11. Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. National Institutes of Health State-of-the-Science Panel. J Natl Cancer Inst Monogr 2004; 32: 9-16.
12. Berger AM. Update on the state of the science: sleep-wake disturbances in adult patients with cancer. Onco Nurs Forum 2009; 36: E165-77.
13. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer-and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 2011; 38: 431-8.
14. Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M. It's not over when it's over: long-term symptoms in cancer survivors-a systematic review. Int J Psychiatry Med 2010; 40: 163-81.
15. Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. National Comprehensive Cancer Network. Oncology (Williston Park). 2000; 14: 151-61.
16. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008; 26: 971-82.
17. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 2004; 11: 279-92.
18. Dantzer R, Kelley KW. Twenty years of research on cytokineinduced sickness behavior. Brain Behav Immun 2007; 21: 153-160.
19. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
20. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 2005; 12: 255-69.
21. Lawrence DP, Kupelnick B, Miller K, Devin D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004; 32: 40-50.
22. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000; 18: 743-53.
23. Cella D, Davis K, Breitbart W, Curt G. Fatigue Coalition. Cancerrelated fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19: 3385-91.
24. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 2006; 106: 751-8.
25. Myers JS. Proinflammatory cytokines and sickness behavior: implications for depression and cancer related symptoms. Oncol Nurs Forum 2008; 35: 802-7.
26. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 2005; 104: 305-13.
27. Greenberg DB, Gray JL, Mannix CM, Eisenthal S and Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage 1993; 8: 196-200.
28. Wratten C, Kilmurray J, Nash S, et al. Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 2004; 59: 160-7.
29. Mills PJ, Parker B, Dimsdale JE, Sadler GR, Ancoli-Israel S. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol Psychol 2005; 69: 85-96.
30. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64: 604-11.
31. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007; 21: 413-27.
32. Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun. 2007; 21: 251-8.
33. Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11: 1757-64.
34. Monk JP, Phillips G, Waite R, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006; 24: 1852-9.
35. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005; 25: 1181-92.
36. Boler J, Enzmann F, Folkers K, Bowers CY, Schally AV. The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem Biophys Res Commun 1969; 37: 705-10.
37. Lechan RM, Fekete C. The TRH neuron: a hypothalamic integrator of energy metabolism. Prog Brain Res 2006; 153: 209-35.
38. Gary KA, Sevarino KA, Yarbrough GG, Prange AJ Jr, Winokur A. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J Pharmacol Exp Ther 2003; 305: 410-6.
39. Yarbrough GG, Kamath J, Winokur A, Prange AJ Jr. Thyrotropinreleasing hormone (TRH) in the neuroaxis: therapeutic effects reflect physiological functions and molecular actions. Med Hypotheses 2007; 69: 1249-56.
40. Gutiérrez-Mariscal M, de Gortari P, López-Rubalcava C, Martínez A, Joseph-Bravo P. Analysis of the anxiolytic-like effect of TRH and the response of amygdalar TRHergic neurons in anxiety. Psychoneuroendocrinology 2008; 33: 198-213.
41. Monga V, Meena CL, Kaur N, Jain R. Chemistry and biology of thyrotropin-releasing hormone (TRH) and its analogs. Curr Med Chem 2008; 15: 2718-33.
42. Kamath J, Yarbrough GG, Prange AJ, Winokur A. The thyrotropinreleasing hormone (TRH)-immune system homeostatic hypothesis. Pharmacol Ther 2009; 121: 20-8.
43. Nillni EA, Sevarino KA. The biology of pro-thyrotropin-releasing hormone derived peptides. Endocr Rev 1999; 20: 599-648.
44. Sun Y, Lu X. Gershengorn MC. Thyrotropin-releasing hormone receptors-similarities and differences. J Mol Endocrinol 2003; 30: 87-97.
45. Pierpaoli W, Lesnikov VA. Effects of long-term intraperitoneal injection of thyrotropin-releasing hormone (TRH) on aging-and obesity-related changes in body weight, lipid metabolism, and thyroid functions. Curr Aging Sci 2011; 4: 25-32.
46. Mellado M, Fernández-Agulló T, Rodríguez-Frade JM, et al. Expression analysis of the thyrotropin-releasing hormone receptor (TRHR) in the immune system using agonist anti-TRHR monoclonal antibodies. FEBS Lett 1999; 451(3): 308-14.
47. Montagne JJ, Ladram A, Nicolas P, Bulant M. Cloning of thyrotropinreleasing hormone precursor and receptor in rat thymus, adrenal gland, and testis. Endocrinology 1999; 140: 1054-9.
48. Klein JR. The immune system as a regulator of thyroid hormone activity. Exp Biol Med (Maywood) 2006; 231: 229-36.
49. Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 2002; 57: 435-55.
50. Pavlov VA, Tracey KJ. Neural regulators of innate immune responses and inflammation. Cell Mol Life Sci. 2004; 61: 2322-31.
51. van Haasteren GA, van der Meer MJ, Hermus AR, et al. Different effects of continuous infusion of interleukin-1 and interleukin-6 on the hypothalamic-hypophysial-thyroid axis. Endocrinology 1994; 135(4): 1336-45.
52. Pang XP, Hershman JM, Mirell CJ, Pekary AE. Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant tumor necrosis factor-alpha (cachectin). Endocrinology 1989; 125: 76-84.
53. Schettini G, Grimaldi M, Landolfi E, et al. Role of interleukin-6 in the neuroendocrine system. Acta Neurol (Napoli) 1991; 13, 361-7.
54. Kamath J, Feinn R, Winokur A. Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study. Support Care Cancer 2012; 20: 1745-53.
55. Van Belle S, Paridaens R, Evers G, et al. Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. Support Care Cancer 2005; 13: 246-54.
56. McNair DM, Lorr M, Droppleman LF. Profile of mood states: manual, Educational and Industrial Testing Service, San Diego. 1981.
57. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1: 79.
58. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigation - a review. Psychopharmacology 1980; 71: 173-9.